Radar · Life Sciences in Seattle
Best Life Sciences Companies in Seattle, United States
The 247 best Life Sciences companies in Seattle, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sana Biotechnology.
By Riya SenguptaFinancials
247companies tracked
$8.6Bdisclosed funding
1unicorns
170have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SEATTLE
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
399kcombined LinkedIn audience
47%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Seattle
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Sana Biotechnology Developer of engineered cell therapies for treating various human diseases | $821M | 71 mo ago | 328 328 → 258 (-21%) · sector median +22% | Steve Harr Co-Founder & CEO | DrupalApple iCloud MailPHP+26 | 361 patents Engineered cell therapies and gene delivery platforms for regenerative and immunomodulatory medicine. | — |
| 2 | Adaptive Biotechnologies Provider of clinical diagnostics, and drug discovery for immune diseases | $419M | 100 mo ago | 609 609 → 654 (+7%) · sector median +22% | Harlan Robins co-founder and chief Scientific Officer | WordPress Block EditorWordPressApple iCloud Mail+28 | 351 patents Immune repertoire sequencing for diagnostics, vaccine response, and engineered T‑cell therapies | 3 partnerships |
| 3 | Avalyn Pharma Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis 57Funding top 14%Growth top 30%News top 30%Moat top 31% All 7 signals ▾Fundingtop 14% Growthtop 30% Newstop 30% Moattop 31% Techtop 40% Globalbottom 39% Marketbottom 36% Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $289M | 10 mo ago | 24 | — | WordPressApple iCloud MailMySQL+25 | — | — |
| 4 | Achieve Life Sciences Developer of plant-based alkaloid for treating smoking cessation 37Funding top 11%News top 42%Moat top 48%Tech top 50% All 7 signals ▾Fundingtop 11% Newstop 42% Moattop 48% Techtop 50% Globalbottom 44% Marketbottom 40% Growthbottom 34% Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $264M | 1 mo ago | 25 25 → 40 (+60%) · sector median +22% | — | WordPress Block EditorWordPressMySQL+17 | — | — |
| 5 | Umoja Biopharma Developer of cancer therapeutics | $263M | 17 mo ago | 168 | Michael Jensen Co-Founder | WordPressMySQLPHP+18 | 132 patents Lentiviral vector production and engineered stem‑cell/immune cell therapies for oncology | — |
| 6 | Truveta 🦄 Provider of healthcare data platform for learning services | $200M | 17 mo ago | 250 250 → 443 (+77%) · sector median +22% | Jay Nanduri Co-Founder & CTO | WordPressApple iCloud MailMicrosoft 365+45 | 17 patents Healthcare data de‑identification, normalization, analytics, and ontology matching platforms. | — |
| 7 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 23 mo ago | 48 48 → 73 (+52%) · sector median +22% | Scott Boyken Co-Founder | — | — | — |
| 8 | Callio Therapeutics Developer of multi-payload antibody-drug conjugates for cancer treatment | $187M | 15 mo ago | — | Jerome Kirkup Co-Founder & Chief Scientific Officer | — | — | — |
| 9 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 13 mo ago | 33 | Clifford Stocks Founder & CEO | — | 56 patents Therapeutic antibodies targeting LILRB2 for immune checkpoint modulation in cancer. | — |
| 10 | Tasso Developer of blood collection device for diagnostic applications | $131M | 54 mo ago | 104 | Erwin Berthier CTO and Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+25 | 106 patents Microfluidic devices for automated collection and handling of bodily fluids | 1 award |
| 11 | Blaze Bioscience Biotechnology company improving cancer patient lives through Tumor Paint technology | $124M | 28 mo ago | 27 | — | Cart FunctionalitySquarespace CommerceSquarespace+11 | 157 patents Patents concentrated in chemistry & materials | — |
| 12 | AltPep Developer of diagnostics and therapeutics for amyloid diseases | $120M | 35 mo ago | 5 | Valerie Daggett Founder & CEO | WordPressApple iCloud MailMySQL+15 | — | 1 launch |
| 13 | Faraday Pharma Biopharmaceutical company pursuing the development of elemental reducing agents | $115M | 43 mo ago | 22 | — | — | — | — |
| 14 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 12 mo ago | 54 54 → 61 (+13%) · sector median +22% | Joseph Victor President & CEO | — | 266 patents Advanced fluorescence microscopy and spectral imaging hardware for multiplexed cellular analysis | 1 launch |
| 15 | Magnolia Medical Integrated system to reduce blood culture sample contamination | $104M | 46 mo ago | 77 77 → 81 (+5%) · sector median +22% | — | WordPressApple iCloud MailMicrosoft 365+21 | 433 patents Medical fluid handling devices for sampling, control, and contamination‑free delivery | — |
| 16 | Kineta Developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases | $104M | 48 mo ago | 12 | — | — | 217 patents Small-molecule PIKfyve inhibitors and heterocyclic kinase‑targeted therapeutics. | — |
| 17 | Parse Biosciences Developer of RNA-sequencing solution-based transcriptome kit to analyze health data | $100M | 30 mo ago | 107 | Geoff Krummel Co-Founder | WordPress Block EditorWordPressSentry+33 | — | 1 job opening · 1 launch |
| 18 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 2 mo ago | 54 | John Mulligan Founder & CEO | WordPressMySQLPHP+21 | — | — |
| 19 | Arzeda Developer of enzyme design technology to bridge the gap by creating synthetic enzymes 80Funding top 20%Patents top 21%Innovation top 26%Growth top 28% All 11 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 26% Growthtop 28% Moattop 28% Talenttop 28% Producttop 40% Markettop 45% Partnerstop 45% Globalbottom 42% Newsbottom 18% Funding: Raised $90.7M across 22 rounds · 22 rounds over 17 yrs (1.3/yr) Patents: 85 patents matched (strict assignee match) · 52 filings since 2022 vs 21 in 2017-21 rank vs industry peers · Fliar Intelligence Index 80/100 | $91M | 9 mo ago | 60 60 → 78 (+30%) · sector median +22% | David Baker Co-Founder | — | 85 patents Biocatalytic production and modification of stevia sweeteners and keto‑sugar derived chemicals | 1 partnership |
| 20 | Curevo Developer of vaccines for the treatment of various diseases 29Funding top 25%Talent top 41%Moat top 43%Patents top 48% All 9 signals ▾Fundingtop 25% Talenttop 41% Moattop 43% Patentstop 48% Techtop 50% Innovationbottom 45% Globalbottom 39% Marketbottom 22% Newsbottom 18% Funding: Raised $86.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $86M | 15 mo ago | 8 | George Simeon CEO | WordPress Block EditorElementorWordPress+29 | 3 patents Herpes zoster and combination vaccine formulations for immunogenic protection | — |
| 21 | Twin Strand Bio Developer of DNA sequencing technology to identify genomic mutations | $84M | 16 mo ago | 70 | Mike Schmitt Co-Founder | WordPressPleskApple iCloud Mail+30 | — | — |
| 22 | Mozart Therapeutics Developer of therapeutics for treating inflammatory and autoimmune diseases | $80M | 36 mo ago | 14 | — | Apache HTTP ServerPaylocityMicrosoft 365+4 | — | — |
| 23 | Proprio Developer of visualization system for surgeries | $74M | 34 mo ago | 52 | Gabriel Jones CEO | Webflowcore-jsjQuery+11 | 125 patents Patents concentrated in health & consumer products | — |
| 24 | Tenpoint Therapeutics Developer of engineered cell-based therapeutics to restore vision 50Funding top 23%Talent top 23%Moat top 31%Growth top 33% All 8 signals ▾Fundingtop 23% Talenttop 23% Moattop 31% Growthtop 33% Techtop 49% Newstop 49% Globalbottom 39% Marketbottom 26% Funding: Raised $70.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 8 named leaders on record · 8 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 4 mo ago | 14 | Jose Sahel Co-Founder | WordPressMySQLMariaDB+25 | — | — |
| 25 | Lumen Developer of biological drugs for the treatment of infectious diseases | $68M | 32 mo ago | 67 | Brian Finrow CEO & Founder | WordPressApple iCloud MailMicrosoft 365+20 | — | — |
| 26 | Know Labs Developer of non-invasive technology for identifying and measuring molecules | $63M | 42 mo ago | 11 | Ron Erickson Founder & Chairman | WixSentryBootstrap+12 | 217 patents Non‑invasive RF/microwave sensing for biomedical SpO₂ and structural health monitoring | — |
| 27 | Aptevo Therapeutics Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology | $57M | 14 mo ago | 45 45 → 56 (+24%) · sector median +22% | Marvin White President and CEO | WordPressMySQLPHP+18 | — | — |
| 28 | A-Alpha Bio Developer of cell-based tool for the measurements of protein interactions | $45M | 24 mo ago | 39 39 → 49 (+26%) · sector median +22% | Randolph Lopez Co-founder & CTO | Apple iCloud MailMicrosoft 365React+11 | — | 1 launch · 1 award |
| 29 | Immusoft Developer of programmed B cell therapies for protein delivery | $44M | 24 mo ago | 20 | Matthew Scholz Founder | — | 66 patents Engineered B cells as living factories for therapeutic protein delivery and disease treatment | — |
| 30 | OtoNexus Developer of ultrasound device to non-invasively detect middle ear infections | $33M | 9 mo ago | 16 | Caitlin Cameron Co-Founder & CEO | — | — | — |
| 31 | Cyrus Biotechnology Developer of cloud-based protein-modelling software for drug discovery | $32M | 17 mo ago | 23 23 → 17 (-26%) · sector median +22% | — | — | — | — |
| 32 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 12 mo ago | 32 32 → 54 (+69%) · sector median +22% | — | WordPressApple iCloud MailMicrosoft 365+21 | — | 1 award |
| 33 | Healionics Manufacturer of synthetic biomaterials and implantable medical devices 27Talent top 15%Moat top 25%Funding top 35%Patents top 42% All 9 signals ▾Talenttop 15% Moattop 25% Fundingtop 35% Patentstop 42% Innovationbottom 47% Globalbottom 40% Techbottom 32% Marketbottom 20% Newsbottom 18% Talent: Analyst team rating 5/5 Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $27M | 6 mo ago | 10 | — | WordPressMySQLPHP+15 | 42 patents Implantable vascular grafts and porous ocular drug‑delivery devices for eye disease treatment | — |
| 34 | Oisín Biotechnologies Developer of genetically targeted intervention therapy for age-related diseases | $25M | 18 mo ago | 18 | Gary Hudson Co-Founder & Chairman | Cart FunctionalitySquarespace CommerceSquarespace+11 | — | — |
| 35 | Virtici Transforms innovations into life-changing medical products through leadership, space, and funding 11Funding top 42%Global bottom 35%Patents bottom 29%Innovation bottom 19% All 4 signals ▾Fundingtop 42% Globalbottom 35% Patentsbottom 29% Innovationbottom 19% Funding: Raised $24.2M across 27 rounds · 27 rounds over 14 yrs (1.9/yr) Global: Single-market focus (United States) rank vs industry peers · Fliar Intelligence Index 11/100 | $24M | 10 mo ago | 9 | — | — | 7 patents Inducing immune tolerance to peptide antigens for allergy and immune activation therapies | — |
| 36 | PAI Life Sciences Translational research for neglected diseases, vaccines, adjuvants, and protein biotherapeutics | $24M | 13 mo ago | 5 | — | — | — | — |
| 37 | Kitotech Medical Developer of a device to close wounds, lacerations, and surgical incisions | $21M | 24 mo ago | 16 | — | — | — | — |
| 38 | Curi Bio Manufacturer of drugs for multiple therapautic areas 60Funding top 25%Growth top 28%Tech top 33%Talent bottom 49% All 8 signals ▾Fundingtop 25% Growthtop 28% Techtop 33% Talentbottom 49% Newsbottom 42% Marketbottom 40% Moatbottom 38% Globalbottom 37% Funding: Raised $21.0M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $21M | 6 mo ago | 47 47 → 57 (+21%) · sector median +22% | Nicholas Geisse CEO | Cart FunctionalitySquarespace CommerceSquarespace+32 | — | — |
| 39 | Archon Bio Provider of computational platform to develop protein therapeutics | $20M | 19 mo ago | — | George Ueda Co-Founder & CTO | Cart FunctionalitySquarespace CommerceSquarespace+23 | — | — |
| 40 | Talus Provider of drug discovery platform for gene regulators | $20M | 14 mo ago | 15 | Alex Federation Co-Founder & CEO | WordPressMySQLPHP+23 | 27 patents Automotive interior storage and organization systems for floor and cargo compartments | — |
| 41 | InBios Innovating immunodiagnostics for infectious diseases, improving global health outcomes | $18M | 13 mo ago | 73 | Estela Raychaudhuri CEO & President | WordPressMySQLPHP+25 | 24 patents Rapid lateral flow immunoassays for detecting viral and parasitic infectious diseases | — |
| 42 | Orlance Developer of a platform to deliver nucleic acid vaccines and related therapies | $14M | 14 mo ago | — | Kristyn Aalto CEO | — | 5 patents Needle‑free drug/medical delivery devices and injection technologies. | — |
| 43 | Accipiter Biosciences Developer of de novo protein therapies for complex diseases treatment | $13M | 7 mo ago | — | Javier Castellanos Co-Founder & CTO | WordPressMySQLPHP+14 | — | — |
| 44 | Synthesize Bio Provider of AI-generated gene expression data for biological research purposes | $10M | 9 mo ago | — | Robert Bradley Co-Founder | WebflowApple iCloud MailGSAP+13 | — | 1 launch |
| 45 | Phase Genomics Provider of laboratory and computational services and products | $6M | 13 mo ago | 19 19 → 14 (-26%) · sector median +22% | — | — | 22 patents High-throughput sequencing-based genome analysis and bacterial lysin therapeutics. | — |
| 46 | Potato Developer of an AI platform for life science research execution | $6M | 14 mo ago | — | Ryan Kosai Co-Founder & CTO | Amazon Web ServicesCloudflareUnpkg+14 | — | — |
| 47 | PETX Optimizing breast cancer therapy with advanced imaging technology | $5M | 15 mo ago | 5 | Paul E. Kinahan Co-Founder | — | — | — |
| 48 | ZipBio Developer of AI-driven platform creating de novo genes and protein therapeutics | $4M | 21 mo ago | — | Roee Farber Co-Founder & CEO | WixSentryUIKit+12 | — | — |
| 49 | Seal Rock Therapeutics Provider of therapeutics for liver fibrosis | $1M | 16 mo ago | 7 | Neil McDonnell Founder & CEO | WebflowApache HTTP Servercore-js+5 | — | — |
| 50 | Kuleon Drug discovery company that utilizes AI-based technology to identify novel serotonergic drugs for targeted… | $1M | 10 mo ago | 5 | David Gilles Co-Founder and CTO | — | 37 patents Design and synthesis of heterocyclic serotonin receptor modulators for neuropsychiatric therapies | — |
Top 12 Life Sciences companies in Seattle
#1
Public · Seattle, Washington · founded 1991 · 25 employees$263.6Mraised▾
Public · Seattle, Washington · founded 1991 · 25 employees
Developer of plant-based alkaloid for treating smoking cessation. The company is developing Cytisinicline, which is a plant-based alkaloid with a binding affinity to the α4β2 nicotine receptor. The candidate is expected to block nicotine cravings and reduce the severity of nicotine withdrawal symptoms.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 11%News
top 42%Moat
top 48%Tech
top 50%Global
bottom 44%Market
bottom 40%Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Post IPO (Apr 2026)
News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY · Top themes: Leadership, Earnings
Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers · 64 engagements/post (1.6× cohort median)
Funding rounds
- Apr 2026Post IPO$180M
- Feb 2024Post IPO$60M
- Nov 2022Post IPO$18.9M
- Aug 2021Grant (prize money)$2.8M
Investors
Propel Bio Partners, Nantahala Capital Management, Sopharma Group, HHS, Frazier Life Sciences, TPG
Tech stack
Apache Http ServerBootstrapCdnjsCloudflareCloudflare Bot ManagementGoogle Tag Manager
#2
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Series B · Seattle, Washington · founded 2021 · 54 employees
Manufacturer of cytokine based drugs
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 22%Talent
bottom 49%Tech
bottom 45%Global
bottom 43%Market
bottom 36%Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Tech: 24 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
Founders & team
Investors
Vivo Capital, Roche, RiverVest Venture Partners, Digitalis Ventures, 3x5 Partners, Codon Capital
#3
Series B · Seattle, Washington · founded 2020 · 14 employees$70Mraised▾
Series B · Seattle, Washington · founded 2020 · 14 employees
Developer of engineered cell-based therapeutics to restore vision. The company is advancing cell-based therapies and in vivo reprogramming to restore vision loss caused by the deterioration of functional tissue for people with degenerative ocular diseases.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 23%Talent
top 23%Moat
top 31%Growth
top 33%Tech
top 49%News
top 49%Funding: Raised $70.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Talent: 8 named leaders on record · 8 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jan 2026Conventional Debt$150M
- Jan 2026Series B$85M
- Jul 2023Series A$70M
- 2021Seed—
Founders & team
Investors
British Patient Capital, F-Prime Capital, Sofinnova Partners, Qiming, Eight Roads Ventures, UCL Technology Fund
Tech stack
AccessibeAnime.JsCookieyesCore-JsElementorFastly
#4
Public · Seattle, Washington · founded 2011 · 24 employees$288.9Mraised▾
Public · Seattle, Washington · founded 2011 · 24 employees
Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis. The company's lead program, Aerodone inhaled pirfenidone provides GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. FDA has granted orphan-drug designation to Genoa for the use of pirfenidone.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 14%Growth
top 30%News
top 30%Moat
top 31%Tech
top 40%Global
bottom 39%Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) · Last round Series D (Jul 2025)
Growth: Fresh capital in last 24 mo
News: 5 BI events in 12 mo (of 12 tracked, 3 types) · +25% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 9k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Jul 2025Series D$100M
- Sep 2023Series C$189.2M
- Apr 2020Series B$35.5M
- 2017Series A—
Investors
F-Prime Capital, Novo Holdings, RiverVest Venture Partners, TPG, Norwest, Pivotal bioVenture Partners China
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#5
Series B · Seattle, Washington · founded 2008 · 60 employees$90.7Mraised▾
Series B · Seattle, Washington · founded 2008 · 60 employees
Developer of enzyme design technology to bridge the gap by creating synthetic enzymes. The proprietary technology combines targeted computational enzyme design and protein optimization with metabolic bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 26%Growth
top 28%Moat
top 28%Talent
top 28%Funding: Raised $90.7M across 22 rounds · 22 rounds over 17 yrs (1.3/yr) · Last round Series B (Aug 2025)
Patents: 85 patents matched (strict assignee match) · 52 filings since 2022 vs 21 in 2017-21 · Latest publication 2026
Innovation: 85 patents (top 21% of patent-holders) · 52 filings since 2022 vs 21 in 2017-21 · 2 product lines
Audience (LinkedIn): 9k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 3 partnerships (incl. MANE) announced in 12 mo
Funding rounds
- Aug 2025Series B$4.5M
- May 2025Grant (prize money)$1.7M
- Apr 2025Grant (prize money)$2.2M
- Oct 2023Series B$38M
Founders & team
Investors
Universal Materials Incubator, Casdin Capital, Conti Ventures, Lewis & Clark Agrifood, Circulate Capital, OS Fund
#6
Series C · Seattle, Washington · founded 2007 · 10 employees$26.6Mraised▾
Series C · Seattle, Washington · founded 2007 · 10 employees
Healionics is a manufacturer of synthetic biomaterials and implantable medical devices. It provides tissue regeneration and device bio integration solutions to medical device manufacturers. It offers sphere-templated angiogenic regeneration (STAR) technology, which provides substrate independent, precision-engineered, and 3D biomaterial scaffolds that enhance the bio-integration and promote healing of implanted medical devices. The company’s products are used in various areas, including wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, and urological/women's health.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Talent
top 15%Moat
top 25%Funding
top 35%Patents
top 42%Innovation
bottom 47%Global
bottom 40%Talent: Analyst team rating 5/5
Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents
Funding: Raised $26.6M across 18 rounds · 18 rounds over 18 yrs (1.0/yr) · Last round Series C (Dec 2025)
Audience (LinkedIn): 724 LinkedIn followers
Funding rounds
- Dec 2025Series C$2M
- Apr 2024Grant (prize money)$953.4K
- Oct 2023Series C$5.5M
- May 2021Series C$5.5M
Investors
Keiretsu Capital, Bellingham Angel Group, Alliance of Angels, Tacoma Angel Network, ZINO Society, Keiretsu Forum
Tech stack
WordpressMysqlPhpContact Form 7Yoast SeoNginx
#7
Series B · Seattle, Washington · founded 2015 · 47 employees$21Mraised▾
Series B · Seattle, Washington · founded 2015 · 47 employees
Manufacturer of drugs for multiple therapautic areas
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 25%Growth
top 28%Tech
top 33%Talent
bottom 49%News
bottom 42%Market
bottom 40%Funding: Raised $21.0M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) · Last round Series B (Dec 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Tech: 35 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare · Observability: Microsoft Clarity
Audience (LinkedIn): 10k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- Dec 2025Series B$10M
- Feb 2025Grant (prize money)$2.3M
- Jan 2025Grant (prize money)$2.1M
- Dec 2023Grant (prize money)$2.3M
Founders & team
Investors
UTC Investment, DS, Dynamk Capital, NIH, HHS, Cascadia Venture Forum
Tech stack
Amazon Web ServicesAngularCallrailCart FunctionalityCloudflareCloudflare Bot Management
#8
Series D · Seattle, Washington · founded 2015 · 33 employees$143.6Mraised▾
Series D · Seattle, Washington · founded 2015 · 33 employees
Developer of immunotherapies for the treatment of cancer. The company uses a proprietary technology platform to discover human antibodies and an immune checkpoint inhibitor (CPI). The company’s lead candidate is OR2805 for the treatment of multiple tumor types.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Moat
top 21%Patents
top 24%Innovation
top 27%Growth
top 28%Talent
bottom 49%Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) · Last round Series D (Apr 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents · Soonicorn
Patents: 56 patents matched (strict assignee match) · 48 filings since 2022 vs 8 in 2017-21 · Latest publication 2026
Funding rounds
- Apr 2025Series D$6M
- May 2023Grant (prize money)$13M
- May 2023Series D$14M
- Feb 2022Conventional Debt$50M
Founders & team
Investors
state.tx.us, Oxford Finance, Baxalta, RiverVest Venture Partners, Qatar Investment Authority, Rice University
#9
Series C · Seattle, Washington · founded 2009 · 54 employees$114.3Mraised▾
Series C · Seattle, Washington · founded 2009 · 54 employees
Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging and analysis).
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 24%Moat
top 29%Patents
top 32%Growth
top 39%Innovation
top 41%Market
top 47%Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) · Last round Grant (prize money) (May 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents · 10 curated direct competitors tracked
Patents: 266 patents matched (strict assignee match) · 35 filings since 2022 vs 105 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2025Grant (prize money)$658.3K
- Jun 2024Series C$20M
- Jul 2023Series C$13.2M
- Sep 2021Series C$24M
Founders & team
Investors
Health Quest Capital, 5AM Ventures, Telegraph Hill Partners, F-Prime Capital, Arboretum Ventures, Agilent
#10
Series C · Seattle, Washington · founded 2010 · 16 employees$32.9Mraised▾
Series C · Seattle, Washington · founded 2010 · 16 employees
Developer of an ultrasound device to non-invasively detect middle ear infections or Otitis Media in both children and adults. The doctor points the device at the eardrum, the device then sends an ultrasound signal that detects if fluid is present behind the eardrum, and if so, what type. Currently, doctors often suggest waiting for 24-48 hours to see if the problem resolves before prescribing antibiotics. According to the founder, OtoNexus's handheld doppler ultrasound will eliminate the need to wait.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$1.2M
- Oct 2022Series C$12.9M
- Dec 2021Series C$1.9M
- Apr 2021Series C—
Founders & team
Investors
Keiretsu Capital, Mindshift Capital, Keiretsu Forum, InnovateHer Seattle, FDA, Children's Hospital of Philadelphia
#11
Series C · Seattle, Washington · founded 2019 · 168 employees$263Mraised▾
Series C · Seattle, Washington · founded 2019 · 168 employees
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 24k LinkedIn followers — 5.9% of this cohort's audience · 242 engagements/post (5.9× cohort median)
Hiring: 1 hiring post in 12 mo (public)
Activity: 1 partnerships · 3 awards (incl. Nona Biosciences) announced in 12 mo
Funding rounds
- Jan 2025Series C$100M
- Jun 2021Series B$210M
- Nov 2020Series A$53M
Founders & team
Investors
SoftBank Vision Fund, Temasek, RTW Investments, Presight Capital, CaaS Capital Management, Qiming
Tech stack
AstraCore-JsDocusignElementorGodaddyGoogle Analytics
#12
Series A · Seattle, Washington · founded 2024$187Mraised▾
Series A · Seattle, Washington · founded 2024
Developer of multi-payload antibody-drug conjugates for cancer treatment. It develops next-generation antibody-drug conjugates (ADCs) with differentiated payload and linker technologies. This targeted delivery of drug combinations to tumor cells aims to maximize therapeutic benefit for cancer patients. A key focus is on HER2-targeted dual-payload ADCs, and the company is advancing these through clinical proof-of-concept. Research and early development leverage systems biology approaches. Clinical development programs are managed from initial design through to global regulatory approvals. Business development activities include partnerships across multiple therapeutic areas and modalities.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Funding rounds
- Mar 2025Series A$187M
Founders & team
Investors
Frazier Life Sciences, Jeito, Novo Holdings, Omega Funds, Clavystbio, Platanus
Funding & investor landscape
$8.6Btotal disclosed funding
172companies funded
962disclosed rounds
2rounds last 90 days
Most active investors
Madrona9 rounds
Notable founders
John Mulligan
Founder & CEO · Bonum Therapeutics
Jose Sahel
Co-Founder · Tenpoint Therapeutics
Lyndon Cruz
Co-Founder · Tenpoint Therapeutics
David Baker
Co-Founder · Arzeda
Daniela Grabs-Rothlisberger
Co-Founder · Arzeda
Nicholas Geisse
CEO · Curi Bio
Clifford Stocks
Founder & CEO · OncoResponse
Joseph Victor
President & CEO · RareCyte
Caitlin Cameron
Co-Founder & CEO · OtoNexus
Michael Jensen
Co-Founder · Umoja Biopharma
Andrew Scharenberg
Co-Founder & CEO · Umoja Biopharma
Jerome Kirkup
Co-Founder & Chief Scientific Officer · Callio Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, even as breakthroughs' overall field-share shrank from 41% to 30%.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements are intensifying rapidly — both topics climbed from ~3 to 62 papers, driving advancements' share from 29% to 35%.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern is rising sharply — papers tripled from 15 to 45 alongside newly emerging animal health and integrated pest management topics.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
How many Life Sciences companies are there in Seattle, United States?
Radar tracks 247 indexable Life Sciences companies headquartered in Seattle, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Seattle, United States?
The Life Sciences companies in Seattle, United States on this list have raised a combined $8.6B in disclosed equity funding across 172 funded companies.
Which is the highest-funded Life Sciences company in Seattle, United States?
Sana Biotechnology is the highest-funded Life Sciences company in Seattle, United States, with $821M in disclosed equity funding.
How many Life Sciences companies in Seattle, United States are funded?
172 of the 247 Life Sciences companies in Seattle, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Seattle, United States?
1 Life Sciences company in Seattle, United States on this list is valued at $1B or more.
Who are the top investors in Seattle, United States Life Sciences companies?
The most active investors in Seattle, United States Life Sciences companies on this list include HHS, Washington Research Foundation, Alexandria, Arch Venture Partners, National Science Foundation.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.